Table 2.
Immunoexpression of DFF40, DFF45, and Bcl-2 in uterine leiomyosarcomas (uLMS)
| Immunoexpression* | Uterine leiomyosarcomas (uLMS) | Uterine myometrium from hysterectomy specimen for leiomyosarcomas (uLMS-M) | Uterine leiomyomas (uLM) | Uterine myometrium from hysterectomy specimen for leiomyomas (uLM-M) | Uterine control myometrium (uM) |
|---|---|---|---|---|---|
| DFF40 | |||||
| Negative | 23 (43.40%) | 4 (7.55%) | 0 (0.00%) | 3 (5.66%) | 4 (7.55%) |
| Low | 23 (43.40%) | 25 (47.17%) | 16 (30.19%) | 28 (52.83%) | 30 (56.60%) |
| Moderate | 7 (13.20%) | 18 (33.96%) | 18 (33.96%) | 18 (33.86%) | 16 (30.19%) |
| High | 0 (0.00%) | 6 (11.32%) | 19 (35.85%) | 4 (7.55%) | 3 (5.66%) |
| DFF45 | |||||
| Negative | 31 (58.49%) | 5 (9.43%) | 1 (1.89%) | 3 (5.66%) | 3 (5.66%) |
| Low | 22 (41.51%) | 42 (79.25%) | 41 (77.36%) | 35 (66.04%) | 40 (75.47%) |
| Moderate | 0 (0.00%) | 6 (11.32%) | 9 (16.98%) | 14 (26.41%) | 10 (18.87%) |
| High | 0 (0.00%) | 0 (0.00%) | 2 (3.77%) | 1 (1.89%) | 0 (0.00%) |
| Bcl-2 | |||||
| Negative | 25 (47.17%) | 11 (20.75%) | 0 (0.00%) | 13 (24.53%) | 9 (16.98%) |
| Low | 25 (47.17%) | 22 (41.51%) | 15 (28.30%) | 15 (28.30%) | 20 (37.74%) |
| Moderate | 3 (5.66%) | 18 (33.97%) | 17 (32.08%) | 19 (35.85%) | 21 (39.62%) |
| High | 0 (0.00%) | 2 (3.77%) | 21 (39.62%) | 6 (11.32%) | 3 (5.66%) |
Notes: Data presented as n (%). Uterine myometrium from hysterectomy specimens for leiomyosarcomas (uLMS-M); leiomyomas (uLM-M); uterine myometrium from hysterectomy specimen for leiomyomas (uLM-M) and uterine control. Samples of uLMS-M and uLM-M were obtained 1 cm from the primary tumor margin.
*
Immunoexpression was described as following: negative: 0; low: 1–2; moderate: 3–4; and high: 6–9.
Abbreviations: DFF40, DNA fragmentation factor 40; DFF45, DNA fragmentation factor 45; Bcl-2, B-cell lymphoma 2 protein.